News
Exclusive: FDA search for new CBER head focused on small group of final candidates
5+ hour, 33+ min ago (68+ words) Endpoints News Ex'clu'sive: FDA search for new CBER head fo'cused on small group of fi'nal can'di'dates The FDA has nar'rowed its search for a new leader of its Cen'ter for Bi'o'log'ics Eval'u'a'tion and Re'search to three to four fi'nal can'di'dates,…...
Windward Bio gets $165 M to take China-derived drug into Phase 3 asthma trial
9+ hour, 5+ min ago (69+ words) Endpoints News Wind'ward Bio gets $165 M to take Chi'na-de'rived drug in'to Phase 3 asth'ma tri'al A Swiss biotech with two ex'per'i'men'tal med'i'cines from Chi'na, plus an in-house dis'cov'ery team, has brought in $165 mil'lion to ad'vance in'to late-stage test'ing. Think we're worth…...
Bristol Myers" pivotal year; Should AI be swinging bigger? ; and more
2+ day, 12+ hour ago (63+ words) Endpoints News Bris'tol My'ers" piv'otal year; Should AI be swing'ing big'ger? ; and more Wel'come back to End'points Week'ly! The last week of April brought a down'pour of news as sev'er'al phar'ma com'pa'nies re'port'ed their first-quar'ter earn'ings. Max Gel'man " Think we're…...
Pfizer delays patent cliff for blockbuster heart drug
6+ day, 4+ hour ago (41+ words) Endpoints News Pfiz'er de'lays patent cliff for block'buster heart drug Pfiz'er is staving off Vyn'damax com'pe'ti'tion for an'oth'er two years. Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source...
Be One joins the VEGF competition, but with a trispecific antibody
6+ day, 7+ hour ago (59+ words) Endpoints News Be One joins the VEGF com'pe'ti'tion, but with a trispe'cif'ic an'ti'body The phar'ma com'pa'ny for'mer'ly known as Bei Gene has plucked an ex'per'i'men'tal can'cer drug from a Chi'nese biotech, aim'ing to go broad'er than its com'peti'tors. Think we're…...
FDA claims trial 'manipulation' tainted approval of Chemo Centryx drug now owned by Amgen
6+ day, 9+ hour ago (67+ words) Endpoints News FDA claims tri'al 'ma'nip'u'la'tion' taint'ed ap'proval of Chemo'Cen'tryx drug now owned by Am'gen The FDA ac'cused Chemo'Cen'tryx of ma'nip'u'lat'ing the re'sults of a piv'otal clin'i'cal tri'al used to ap'prove the drug Tavneos, es'ca'lat'ing the agency's ef'fort to pull…...
Lilly strikes second partnership this year for recombinase-based gene editing
6+ day, 11+ hour ago (62+ words) Endpoints News Lil'ly strikes sec'ond part'ner'ship this year for re'com'bi'nase-based gene edit'ing Decades be'fore CRISPR gene edit'ing was in'vent'ed, sci'en'tists tried to ma'nip'u'late genes with en'zymes called re'com'bi'nas'es. The pro'teins were pre'cise but proved tricky to use " Think we're worth…...
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what's next
1+ week, 6+ hour ago (66+ words) Endpoints News Q&A: In'tel'lia CEO talks first Phase 3 CRISPR read'out and what's next In'tel'lia Ther'a'peu'tics re'port'ed this morn'ing on the Phase 3 suc'cess of a gene edit'ing treat'ment for hered'i'tary an'gioede'ma, a dis'ease that caus'es un'pre'dictable, dis'fig'ur'ing and " Think we're worth…...
Exclusive: Fathom raises $47 M, blending AI and physics in drug discovery
1+ week, 11+ hour ago (62+ words) Endpoints News Ex'clu'sive: Fath'om rais'es $47 M, blend'ing AI and physics in drug dis'cov'ery In the ear'ly 2000s, way be'fore AI be'came a ubiq'ui'tous buzz'word in biotech, bil'lion'aire sci'en'tist David Shaw was build'ing su'per'com'put'ers to study mol'e'cules at his " Think we're worth…...
Investment in UK biotechs'shows early signs of recovery, report says
1+ week, 23+ hour ago (63+ words) Investment in UK biotechs shows early signs of recovery, report says'Endpoints News In'vest'ment in UK biotechs shows ear'ly signs of re'cov'ery, re'port says Af'ter a lull in mid-2025, in'vest'ment in UK biotechs ap'pears to be pick'ing up, ac'cord'ing to da'ta from…...